Insys Therapeutics Inc (NASDAQ:INSY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Insys Therapeutics Inc develops and commercializes drugs delivery systems targeting the oncology space. The company manufactures cannabinoid formulation, and sublingual spray drug delivery technology for the US and Europe markets. Insys Therapeutics Inc has a market cap of $421.852 million; its shares were traded at around $5.68 with and P/S ratio of 4.32.
For the last quarter Insys Therapeutics Inc reported a revenue of $16.4 million, compared with the revenue of $31.49 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $82.1 million, a decrease of 41.7% from the previous year. For the last five years Insys Therapeutics Inc had an average revenue decline of 7.1% a year.
The reported loss per diluted share was $1.68 for the year, an increase of -46.8% from previous year. The Insys Therapeutics Inc had an operating margin of -135.17%, compared with the operating margin of -42.18% a year before. The 10-year historical median operating margin of Insys Therapeutics Inc is -42.18%. The profitability rank of the company is 5 (out of 10).
At the end of the fiscal year, Insys Therapeutics Inc has the cash and cash equivalents of $31.6 million, compared with $32.0 million in the previous year. The company had no long term debt. The interest coverage to the debt is 1.9, which is not a favorable level. Insys Therapeutics Inc has a financial strength rank of 6 (out of 10).
At the current stock price of $5.68, Insys Therapeutics Inc is traded at close to its historical median P/S valuation band of $5.99. The P/S ratio of the stock is 4.32, while the historical median P/S ratio is 4.52. The stock lost 22.03% during the past 12 months.
For the complete 20-year historical financial data of INSY, click here.
No comments:
Post a Comment